Combination therapy of an anti CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor

• 收藏
• 分享

专利权人:

F. Hoffmann-La Roche AG

发明人:

Klein, Christian,Herting, Frank,Dangl, Markus

申请号：

AU2016267564

公开号：

AU2016267564A1

申请日:

2016.05.23

申请国别(地区):

AU

年份:

2017

代理人:

摘要：

The present invention is directed to the combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Lyl antibody and a Bcl-2 inhibitor and a MDM2 inhibitor. Preferably, the anti-CD20 antibody is obinutuzumab. Preferably, the Bcl-2 inhibitor is Venetoclax. Preferably, the MDM2- inhibitor is RG7388.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/